ClearPoint Neuro, Inc.

What they do

ClearPoint Neuro develops and sells the ClearPoint system (hardware, disposables, software) for targeting and guiding deep brain stimulation, biopsies, laser ablation, and drug infusion in the brain. It also offers the SmartFrame OR and SmartFrame Array for operating room use, and the ClearPoint Prism laser ablation system. Through the 2025 IRRAS acquisition, it added the IRRAflow system for neurocritical care fluid management. A second business line provides preclinical and clinical services (e.g., protocol design, in vivo studies, GLP services) to more than 60 biopharma customers developing gene and cell therapies.

Revenue drivers

• Medical device sales (ClearPoint system, disposables, and related products) — Core recurring revenue from disposable components and capital equipment placements; includes SmartFrame OR, Prism laser system, and IRRAflow, with overall revenue growth driven by installed base expansion.
• Biologics and Drug Delivery segment — Revenue from product sales (e.g., SmartFlow cannula) and services to biopharma partners; in Q2 2026 this segment declined 15% year-over-year due to lower product shipments for new trial initiations, partially offset by growth in preclinical service revenue.
• Preclinical services (ClearPoint Advanced Laboratories) — Growing revenue stream from consulting, in vivo biology services in large and small models, and GLP services; facility now in operation and first GLP work expected in H1 2027.

Recent performance

Q2 2026 revenue was $10.9 million, up 18% year-over-year, but Biologics and Drug Delivery revenue fell 15%. Full-year 2025 revenue was $37.0 million with a net loss of $25.5 million and operating cash flow of -$23.9 million. The company reported a net loss each year from 2021 to 2025, with losses widening in 2025. As of June 30, 2026, cash was $29.4 million, total assets $86.7 million, and long-term debt $50.2 million.

Strategy

Management prioritizes establishing ClearPoint Neuro as the leading neuro cell and gene therapy delivery company, investing over $200 million and building a partner ecosystem. They are expanding clinical capacity and installed base to prepare for potential commercial approvals of partner therapies as early as 2027. The company entered a 10-year focused ultrasound drug delivery partnership with SONOCARE Lab at Sungkyunkwan University and showcased a robotic platform and Harmony 1.0 software at trade shows. Commercial structure was reorganized in Q2 to emphasize installed base growth and clinical case support.

Risks

• Dependence on biopharma partners — A significant portion of revenue relies on partners' clinical trial progress and regulatory approvals; delays or failures could reduce demand for products and services.
• Continued losses and cash burn — Net losses and negative operating cash flow persist (e.g., $25.5M net loss and -$23.9M OCF in 2025), requiring ongoing financing to sustain operations.
• High debt level — Long-term debt of $50.2M versus cash of $29.4M creates refinancing and liquidity risk, especially if revenue growth stalls.
• Competitive and regulatory risks — The neurosurgical device market faces competition from larger players (e.g., Medtronic, Abbott, Elekta) and regulatory approvals for new products and partner therapies may be delayed.

Outlook

Management expects 10-15 clinical trials using ClearPoint technology to be enrolling within the next 18 months and approximately 10 partner data readouts. FDA feedback on BLA submissions and global regulatory progress could lead to commercial cell and gene therapies by end of 2027, which would boost demand for delivery products and services. Preclinical services revenue is expected to return the Biologics segment to growth in Q3 2026 with CAL facility now operational.